Urokinase-type plasminogen activator (uPA), a member of the plasminogen activation (PA) system, and its receptor, the urokinase plasminogen activator receptor (uPAR), have both been linked to poor prognosis in several cancer types [5]–[7], including OSCC [8]–[10]. The gene discussed is PLAUR; the disease is cancer.